Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy

ABSTRACT: Analysis of UK blood transcriptional profiles before treatment to indentify changes that occur during (2 weeks, 2 months), at the end of treatment (6 months) and after treatment (12 months) Analysis of South African blood transcriptional profiles before treatment to indentify changes that occur during (2 weeks, 2 months), at the end of treatment (6 months) and after treatment (12 months)

ORGANISM(S): Homo sapiens

PROVIDER: GSE40553 | GEO | 2012/10/01

SECONDARY ACCESSION(S): PRJNA174336

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy

Project description:Analysis of UK blood transcriptional profiles before treatment to indentify changes that occur during (2 weeks, 2 months), at the end of treatment (6 months) and after treatment (12 months) Analysis of South African blood transcriptional profiles before treatment to indentify changes that occur during (2 weeks, 2 months), at the end of treatment (6 months) and after treatment (12 months) Total RNA obtained from active TB patients before, during and after treatment

2012-10-01 | E-GEOD-40553 | biostudies-arrayexpress

Gene expression profiling in peripheral blood cells of patients with rheumatoid arthitis in response of anti-TNF-alpha

Project description:The goal of this study was to characterize the effects of anti-TNF-alpha treatments on gene expression in peripheral blood mononuclear cells. 8 women were submitted to a 12 weeks treatments with Etanercept or Adalimumab. Peripheral blood mononuclear cells were taken before and after the treatment. The samples from the same patients (obtained before and after the 12 weeks of treatment) were compared on the same microarray. Sample taken before the treatment was considered as the control.

2011-07-13 | GSE12897 | GEO

Analysis of Rosiglitazone therapy on adipose tissue in type 2 diabetic patients

Project description:The goal of this study was to analyse the effect of a 12 weeks treatment with rosiglitazone on gene expression in adipose tissue of type 2 diabetic patients. Diabetic patients were treated with rosiglitazone, agonist of PPAR gamma, during 12 weeks. Adipose tissue biopsies were taken before and after the treatment.

2018-04-20 | GSE12793 | GEO

First ruxolitinib treatment of human alopecia areata patients

Project description:Two patients with alopecia areata were treated with systemic ruxolitinib. Skin biopsies were taken before starting treatment and 12 weeks after starting treatment. We used microarrays to assess changes in gene expression of affected skin before and after starting treatment

2014-08-17 | GSE58573 | GEO

Analysis of genomic aberrations by array comparative genomic hybridization (aCGH) of tumor tissues of mice after 12 months on CD-HFD (n= 9) or 12 months on CD-HFD plus 8 weeks treatment with α-PD-1 (n= 12)

Project description:Genomic DNA was extracted from tumors that developed in C57BL/6 mice fed with CD-HFD for 12 months alone or fed with CD-HFD for 12 months followed by 8 weeks of treatment with anti-PD-1. DNA extracted from five pooled tail-clips of C57BL/6 mice was used as reference DNA.

2020-08-31 | GSE144875 | GEO

Carbon fixation (endogenous sugar) and light-dependent gene expression

Project description:Internal sugar and light specific dependent regulation of leaf gene expression was addressed by changing [CO2] to lower than compensation point [CO2] in combination with light or prolonged darkness. Plants were grown on soil in a 12/12 h light/dark rhythm at 20°C day and night and under normal [CO2]. 5 weeks after germination, the above-ground rosettes of the non-flowering plants were harvested, 12 plants per sample. Plants were harvested 4hrs after the end of night (i) under low (< 50 ppm) [CO2] and 150 µE fluorescent light , (ii) under normal [CO2] and light, and, (iii) under low [CO2] and prolonged darkness. The low [CO2] treatment started 30 min before the end of night and stopped with harvesting. Keywords: repeat

2005-12-01 | GSE3423 | GEO

Gene expression analysis of Triple-negative breast tumors from young and aged mice

Project description:Whole tissue RNA-seq analysis of mammary tumors from old (>12 months) and young (8-10 weeks) of mice after treatment with isotype, anti-CTLA4 or anti-PDL1 treatments.

2020-04-05 | GSE130472 | GEO

McLean1991 - Behaviour of HIV in the presence of zidovudine

Project description:A new mechanism is proposed for the apparent breakthrough of HIV that occurs approximately 6 months after the commencement of therapy with zidovudine (AZT). Using a simple mathematical model of the interacting population dynamics of HIV and its major host cell in the circulation (the CD4+ lymphocyte), predicted patterns of HIV plasma viraemia in the weeks following treatment with zidovudine are generated. These are in close agreement with observed patterns despite the fact that the model contains no mechanisms for the development of drug-resistant strains of virus. It is suggested that the patterns of viral abundance observed during the first 6 months after treatment may be the result of non-linearities in the interactions between HIV and CD4+ cells, and that it is only after the first post-treatment burst of viral production that drug resistance plays an important role.

2020-10-15 | BIOMD0000000967 | BioModels

RNA-seq of zebrafish brain, liver and skin during perturbation with rotenone at young and old age

Project description:Zebrafish of two different age groups (12 and 36 months) were treated with low amounts of rotenone (mild stress) and compared to untreated zebrafish. Two different durations were used (3 and 8 weeks). Illumina sequencing (HiSeq2000) was applied to generate 50bp single-end reads. Jena Centre for Systems Biology of Ageing - JenAge (www.jenage.de)

2016-04-21 | GSE66362 | GEO

Canakinumab treatment for recent-onset type 1 diabeties mellitus: a multicenter randomized, placebo-controlled trial

Project description:Background: Blocking the action of the pro-inflammatory cytokine interleukin-1 (IL-1) reduces beta-cell secretory dysfunction and apoptosis in vitro, diabetes incidence in animal models of Type 1 diabetes mellitus (T1D), and glycaemia via improved beta-cell function in patients with T2D. We hypothesised that canakinumab, a monoclonal antibody to IL-1B, improves beta-cell function in patients with new-onset T1D. Methods: In an individually randomised, two-group parallel trial involving 12 sites in US, 69 patients aged 6-45 with T1D, < 12 weeks of symptoms, and assigned by centralised computer-generated blocked randomisation with locked computer-file concealment to treatment with 2 mg/kg (maximum 300 mg) canakinumab (n=45) or placebo (n=22) monthly for 12 months as add-on to conventional therapy. Participants and care-givers, but not data monitoring unit, were masked to group assignment. The primary end-point was change in the two-hour area-under-the-curve C-peptide response to MMT 12 months.

2015-10-01 | GSE68049 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data